16:02:38 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-30 Kvartalsrapport 2024-Q3
2024-07-18 Kvartalsrapport 2024-Q2
2024-04-25 Kvartalsrapport 2024-Q1
2024-03-20 Ordinarie utdelning OKDAV 0.07 EUR
2024-03-20 Ordinarie utdelning OKDBV 0.07 EUR
2024-03-19 Årsstämma 2024
2024-02-16 Bokslutskommuniké 2023
2023-10-31 Kvartalsrapport 2023-Q3
2023-07-21 Kvartalsrapport 2023-Q2
2023-04-27 Kvartalsrapport 2023-Q1
2023-03-22 Ordinarie utdelning OKDAV 0.06 EUR
2023-03-22 Ordinarie utdelning OKDBV 0.06 EUR
2023-03-21 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-03-16 Ordinarie utdelning OKDBV 0.04 EUR
2022-03-16 Ordinarie utdelning OKDAV 0.04 EUR
2022-03-15 Årsstämma 2022
2022-02-18 Bokslutskommuniké 2021
2021-10-27 Kvartalsrapport 2021-Q3
2021-07-20 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-17 Ordinarie utdelning OKDBV 0.03 EUR
2021-03-17 Ordinarie utdelning OKDAV 0.03 EUR
2021-03-16 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-04-24 Kvartalsrapport 2020-Q1
2020-03-18 Ordinarie utdelning OKDAV 0.09 EUR
2020-03-18 Ordinarie utdelning OKDBV 0.09 EUR
2020-03-17 Årsstämma 2020
2020-02-07 Bokslutskommuniké 2019
2019-07-17 Kvartalsrapport 2019-Q2
2019-03-20 Ordinarie utdelning OKDAV 0.09 EUR
2019-03-20 Ordinarie utdelning OKDBV 0.09 EUR
2019-03-19 Årsstämma 2019
2018-11-01 Kvartalsrapport 2018-Q3
2018-07-18 Kvartalsrapport 2018-Q2
2018-04-27 Kvartalsrapport 2018-Q1
2018-03-20 Ordinarie utdelning OKDBV 0.09 EUR
2018-03-20 Ordinarie utdelning OKDAV 0.09 EUR
2018-03-19 Årsstämma 2018
2018-02-13 Bokslutskommuniké 2017
2017-10-25 Kvartalsrapport 2017-Q3
2017-07-21 Kvartalsrapport 2017-Q2
2017-04-28 Kvartalsrapport 2017-Q1
2017-03-15 Ordinarie utdelning OKDAV 0.14 EUR
2017-03-15 Ordinarie utdelning OKDBV 0.14 EUR
2017-03-14 Årsstämma 2017
2017-02-13 Bokslutskommuniké 2016
2016-10-20 Kvartalsrapport 2016-Q3
2016-07-19 Kvartalsrapport 2016-Q2
2016-04-22 Kvartalsrapport 2016-Q1
2016-03-15 Ordinarie utdelning OKDBV 0.13 EUR
2016-03-15 Ordinarie utdelning OKDAV 0.13 EUR
2016-03-14 Årsstämma 2016
2016-02-05 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-09-09 Kapitalmarknadsdag 2015
2015-07-17 Kvartalsrapport 2015-Q2
2015-04-23 Kvartalsrapport 2015-Q1
2015-03-31 Ordinarie utdelning OKDAV 0.00 EUR
2015-03-31 Ordinarie utdelning OKDBV 0.00 EUR
2015-03-30 Årsstämma 2015
2015-02-06 Bokslutskommuniké 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-07-24 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-03-25 Ordinarie utdelning OKDBV 0.00 EUR
2014-03-25 Ordinarie utdelning OKDAV 0.00 EUR
2014-03-24 Årsstämma 2014
2014-02-07 Bokslutskommuniké 2013
2013-10-24 Kvartalsrapport 2013-Q3
2013-07-25 Kvartalsrapport 2013-Q2
2013-04-25 Kvartalsrapport 2013-Q1
2013-03-21 Ordinarie utdelning OKDBV 0.09 EUR
2013-03-21 Ordinarie utdelning OKDAV 0.09 EUR
2013-03-20 Årsstämma 2013
2013-02-07 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-07-26 Kvartalsrapport 2012-Q2
2012-04-26 Kvartalsrapport 2012-Q1
2012-03-27 Ordinarie utdelning OKDAV 0.08 EUR
2012-03-27 Ordinarie utdelning OKDBV 0.08 EUR
2012-03-26 Årsstämma 2012
2012-02-09 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-08-04 Kvartalsrapport 2011-Q2
2011-04-28 Kvartalsrapport 2011-Q1
2011-04-07 Ordinarie utdelning OKDAV 0.05 EUR
2011-04-07 Bonusutdelning OKDBV 0.13
2011-04-07 Bonusutdelning OKDAV 0.13
2011-04-07 Ordinarie utdelning OKDBV 0.05 EUR
2011-03-07 Bokslutskommuniké 2010
2010-04-08 Ordinarie utdelning OKDAV 0.12 EUR
2010-04-08 Ordinarie utdelning OKDBV 0.12 EUR
2010-04-07 Årsstämma 2010
2010-02-11 Bokslutskommuniké 2009
2009-04-17 Ordinarie utdelning OKDAV 0.08 EUR
2009-04-17 Ordinarie utdelning OKDBV 0.08 EUR
2008-03-18 Ordinarie utdelning OKDAV 0.08 EUR
2008-03-18 Ordinarie utdelning OKDBV 0.08 EUR
2007-03-14 Ordinarie utdelning OKDAV 0.06 EUR
2007-03-14 Ordinarie utdelning OKDBV 0.06 EUR

Beskrivning

LandFinland
ListaMid Cap Helsinki
SektorHälsovård
IndustriLäkemedel & Handel
Oriola är en läkemedelskoncern med särskilt fokus inom distribution av läkemedel till andra aktörer inom branschen. Bolaget erbjuder tjänster till apotek och övriga läkemedelsbolag, vilket exempelvis innefattar förhandlingar med leverantörer och distribution av produkter. Idag innehas störst verksamhet inom Norden och Baltikum. Huvudkontoret ligger i Esbo.
2023-07-21 07:30:00

Oriola Corporation Stock Exchange Release 21 July 2023 at 8.30 a.m. EEST

Oriola Corporation's Half-Year Report January-June 2023

Solid performance in Distribution business, profitability burdened by Dose Sweden

April-June 2023 highlights
  • Invoicing was EUR 904.3 (903.9) million and slightly above the previous year's level. On a constant currency basis, invoicing increased by 6.0% and was EUR 958.2 million.
  • Net sales decreased by 2.8% to EUR 383.6 (394.6) million. On a constant currency basis, net sales increased by 3.0% and were EUR 406.5 million.
  • Adjusted EBIT was EUR 3.4 (5.5) million. On a constant currency basis, the adjusted EBIT was EUR 3.6 million.
  • EBIT was EUR 3.2 (7.0) million and included adjusting items of EUR -0.2 (1.5) million. On a constant currency basis, EBIT was EUR 3.4 million.
  • Profit for the period totalled EUR 1.2 (5.5) million and earnings per share were EUR 0.01 (0.03).
January-June 2023 highlights
  • Invoicing decreased by 1.6% to EUR 1,762.7 (1,790.6) million. On a constant currency basis, invoicing increased by 3.6% and was EUR 1,854.9 million.
  • Net sales decreased by 3.8% to EUR 738.4 (767.4) million. On a constant currency basis, net sales increased by 1.2% and were EUR 776.9 million.
  • Adjusted EBIT was EUR 6.9 (10.2) million. On a constant currency basis, the adjusted EBIT was EUR 7.3 million.
  • EBIT was EUR 6.7 (10.3) million and included adjusting items of EUR -0.2 (0.1) million. On a constant currency basis, EBIT was EUR 7.1 million.
  • Profit for the period totalled EUR 2.3 (7.6) million and earnings per share were EUR 0.01 (0.04). 

[][][][][]
Key figures 2023 2022 Change 2023 2022 Change 2022
EUR million 4-6 4-6 % 1-6 1-6 % 1-12
Continuing
operations
Invoicing 904.3 903.9 0.0 1,762.7 1,790.6 -1.6 3,568.0
Net sales 383.6 394.6 -2.8 738.4 767.4 -3.8 1,515.5
Adjusted 3.4 5.5 -38.7 6.9 10.2 -32.3 19.7
EBIT[1, 2]
EBIT 3.2 7.0 -54.7 6.7 10.3 -35.3 9.5
Adjusted EBIT 0.9 1.4 0.9 1.3 1.3
%
EBIT % 0.8 1.8 0.9 1.3 0.6
Profit for 1.2 5.5 -77.6 2.3 7.6 -69.3 4.8
the period
Earnings per 0.01 0.03 -77.6 0.01 0.04 -69.3 0.03
share, EUR,
continuing
operations
Earnings per - 0.04 - 0.07 -0.04
share, EUR,
discontinued
operations

Net cash flow 19.2 38.9 -23.4 67.7 77.9
from
operating
activities[3]

Gearing, % 4.5 -4.6 -10.5
[3]
Equity ratio, 21.2 19.8 23.8
%[ 3]
Return on 3.9 4.6 2.4
capital
employed
(ROCE), % [3]

1 Year 2022 Adjusted EBIT and EBIT have been restated and exclude the share of result in joint venture.
2 Adjusting items are specified in note Adjusting items.
3 Comparative figures include continuing and discontinued operations.

In order to reflect the underlying business performance and to enhance comparability between financial periods, Oriola discloses certain performance measures of historical performance, financial position and cash flows, as permitted in the "Alternative performance measures" guidance issued by the European Securities and Markets Authority (ESMA). These measures should not be considered as a substitute for measures of performance in accordance with the IFRS. The calculation methods of these measures are provided in note Alternative performance measures in the notes to this Half Year Financial Report.

Outlook for 2023

Oriola expects the adjusted EBIT to remain on the same level compared to 2022.

The outlook takes into consideration the significant negative impact on Oriola's profitability from the loss of public tenders and consequently of patients in the dose dispensing business in Sweden. The dose dispensing business in Sweden will focus on new customer segments to develop the business. Furthermore, the recent overall inflationary environment and related cost pressures may have an impact on Oriola's profitability.

The adjusted EBIT in 2022 was EUR 19.7 million, excluding the contribution from the joint venture company Swedish Pharmacy Holding AB.

CEO Katarina Gabrielson:

A stable second quarter with net sales growing by 3% to EUR 407 million in constant currency. Growth was driven by our core business, the Distribution of pharmaceuticals and traded goods, where we saw solid development both in Sweden and Finland supported by a growing market and stable market shares. For Oriola, the significant headwind from the weak Swedish krona in the second quarter was visible mainly in the reported invoicing and net sales figures. Due to the further weakening of the Swedish krona in the second quarter, the negative impact was also to some extent visible on adjusted EBIT.

In the second quarter, Oriola's profitability declined from the previous year to EUR 3.4 (5.5) million due to the low volumes in the Swedish Dose dispensing business, as communicated earlier. Overall cost inflation has stabilised while costs have remained at a high level. To mitigate the inflationary pressure, we have implemented price increases across all businesses. Our operating expenses were below last year's level largely driven by cost restructuring in the Swedish Dose dispensing business, improved efficiency in our Swedish operations and overall strict cost control. Our financial position is still strong with positive cash flow in the second quarter and a strong balance sheet.

Profitability of our joint venture company Kronans Apotek continued to improve driven by good customer inflow in pharmacies and synergy savings achieved from integration. We booked a positive contribution of EUR 0.2 million from Kronans Apotek to our profit and loss account in the second quarter.

Oriola's focus continues to be the long-term transformation of the company by developing our commercial and supply chain excellence while ensuring profitability, efficiency and a collaborative culture. I am very pleased that our new commercial operating model, which extensively focuses on collaboration across the markets, has already shown good progress with the signing of new distribution contracts. We have also continued to strengthen our commercial capabilities by sales training focusing on account management to support a unified customer experience, and our new customer segmentation provides focus and enhances understanding of how we can create relevance and growth. In supply chain, we have continued to simplify and harmonise processes across Oriola, including core IT systems. We have also improved our efficiency in deliveries through improved demand-supply planning and tighter collaboration with the sales teams. Developing a strong culture is one of our key priorities, and during the second quarter we engaged with our people to renew Oriola's value descriptions.

At Oriola, we believe that a sustainable future starts with health, and therefore sustainability is embedded in everything we do. Our sustainability work has been guided by ambitious long-term goals and a systematic approach to development. In June, Oriola was awarded the gold medal in the EcoVadis sustainability rating with a result placing us among the top 5% performing companies worldwide. This is a great recognition and demonstrates our commitment to sustainability.

Looking at the full year, we continue to expect Oriola's adjusted EBIT to remain on the same level compared to last year. We expect the volumes in the Swedish Dose business to remain at the current level during the second half. We expect the pharmaceutical distribution market to continue to grow. Our strength is in the Distribution business that has performed strongly during the first half of the year and where we have new customers onboarding during the second half. We continue with price increases and strict cost control to mitigate the high cost inflation. I am very pleased with the achievements of our people during the second quarter, and this is a great opportunity to thank everyone for their dedication and hard work.

Disclosure procedure

This stock exchange release is a summary of Oriola Corporation's Half-Year Report January-June 2023. The complete report is attached to this release in pdf format and is also available on Oriola's website at www.oriola.com/investors.

Analyst and investor meeting at 10.00 a.m. EEST

Oriola's CEO Katarina Gabrielson and CFO Timo Leinonen will present the Half-Year Report at a live webcast meeting today at 10.00 a.m. EEST. Please join meeting here: https://oriola.videosync.fi/q2-2023

Financial reporting in 2023

Oriola will publish Interim Report for January-September 2023 on Tuesday 31 October 2023.

Further information:
Timo Leinonen
CFO
email: timo.leinonen@oriola.com

Mikael Wegmüller
VP, Communications and Sustainability
email: mikael.wegmuller@oriola.com

Distribution:
Nasdaq Helsinki Ltd
Key media